


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 22, 2004 Signature: 
(Danielle L. Herritt)

DPW 1651
Docket No.: NBI-108US
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Anne Clark, *et al.*

Serial No.: 10/030,350

Filed: January 7, 2002

For: **COMPOUNDS FOR INHIBITING
DISEASES AND PREPARING CELLS FOR
TRANSPLANTATION**

Attorney Docket No.: NBI-108US

Group Art Unit: 1651

Examiner: S. M. Hanley

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. These references were cited in an International Search Report dated July 7, 2000 and a Written Opinion dated May 7, 2003, during the prosecution of PCT/GB00/02623 which corresponds to the above referenced application. A copy of the report, the opinion, and each cited publication is enclosed.

Additionally, Applicants provide the full text of the Westermarck reference cited by the Examiner in the Office Action dated June 3, 2004 (B1).

Applicants also wish to bring to the Examiner's attention the following related U.S. patent document and co-pending applications:

U.S. Patent No. 6,562,836 B1 (A1);

U.S. Publication No. 2004/0198832 A1; and

US. Publication No. 2004/0248876 A1.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP




Danielle L. Herritt, Esq.
Registration No. 43,670
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: December 22, 2004

GAD/EAH/DLH/DLN/rl
Enclosures



LAHIVE
&
COCKFIELD
LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. McKENNA
VINCENT P. LOCCISANO
JAMES M. MCKENZIE

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
JAMES H. VELEMA
W. ELANA WANG
CYNTHIA M. GILBERT

* Admitted in TX only
** Admitted in CT only

December 22, 2004

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/030,350
For: **COMPOUNDS FOR INHIBITING DISEASE AND PREPARING
CELLS FOR TRANSPLANTATION**
Inventors: Anne Clark, *et al.*
Filed: January 7, 2002
Our Ref. No.: NBI-108US

Dear Sir:

I enclose herewith for filing in the above-identified application the following:


1. Information Disclosure Statement;
2. PTO Form SB/08;
3. A copy of the International Search Report;
4. A copy of the Written Opinion;
5. Copies of references cited in PTO Form SB/08 (19); and
6. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.


I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:

December 22, 2004

Date


Danielle L. Herritt, Esq., Registration No. 43,670

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Danielle L. Herritt, Esq.
Registration No. 43,670
Attorney for Applicants



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/030,350
				Filing Date	January 7, 2002
				First Named Inventor	Anne Clark
				Art Unit	1651
				Examiner Name	Susan Marie Hanley
Sheet	1	of	2	Attorney Docket Number	NBI-108US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	6,562,836 B1	05-13-2003	Szarek, <i>et al.</i>	
	A2	2004/0198832 A1	10-07-2004	Szarek, <i>et al.</i>	
	A3	2004/0248876 A1	12-09-2004	Szarek, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A4	WO 93/03714 A2	03-04-1993	The Upjohn Company		
	A5	WO 94/22437 A2,A3	10-13-1994	Queen's Univ. at Kingston		
	A6	WO 94/27602 A1	12-08-1994	Cortex Pharmaceuticals, Inc.		
	A7	WO 96/28187 A1	09-19-1996	Queen's Univ. at Kingston		
	A8	WO 96/37612 A1	11-28-1996	Pfizer, Inc.		
	A9	WO 98/11923 A1	03-26-1998	Baylor College of Medicine		
	A10	WO 99/40909 A1	08-19-1999	Neurochem, Inc.		
	A11	WO 00/64420 A2	11-02-2000	Queen's Univ. at Kingston		
	A12	WO 00/71101 A2,A3	11-30-2000	Queen's Univ. at Kingston		
	A13	WO 01/03680 A2	01-18-2001	Isis Innovation Limited		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	A14	Copani, A., <i>et al.</i> "Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by β -amyloid peptide." <i>Mol. Pharmacol.</i> 1995 May; 47(5):890-7.			
	A15	Hutchings, R., <i>et al.</i> "The effect of excitotoxin antagonists on ibotenic ac-induced alteration of APP mRNA hippocampal expression" <i>Journal of Pharmacy and Pharmacology.</i> 1995 Dec; 47(12B):1131.			
	A16	Pache, D.M., <i>et al.</i> "Effect of selective excitatory amino acid antagonists on excitotoxin-induced changes in APP MRNA expression." <i>Pharmacology Reviews and Communications.</i> 1999; 10(3):205-12.			
	A17	Schwarcz, R., <i>et al.</i> "Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders." <i>Lancet.</i> 1985 Jul 20; 2(8447):140-3.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/030,350
				Filing Date	January 7, 2002
				First Named Inventor	Anne Clark
				Art Unit	1651
				Examiner Name	Susan Marie Hanley
Sheet	2	of	2	Attorney Docket Number	NBI-108US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Westermarck, G.T., <i>et al.</i> "A comparison of amyloid deposition in human and transgenic mouse islets of langerhans transplanted into nude mice." <i>Amyloid and Amyloidosis</i> 1998, Pros. Int. Symp. Amyloidosis, 8 th , Rochester, Minn; 545-547.	
	B2	"Use of metabotropic agonists in progressive neurodegenerative diseases", <i>Expert Opinion on Therapeutic Patents</i> , 1995; 5(5):491-3.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--